A split-mouth placebo-controlled study to determine the effect of amorphous calcium phosphate in the treatment of dentine hypersensitivity.
Many treatments for dentine hypersensitivity are formulated to directly or indirectly occlude the open dentinal tubules associated with the condition. Combining solutions of calcium chloride and potassium phosphate can result in the precipitation of amorphous calcium phosphate. Such a system applied to exposed dentine could occlude dentinal tubules and reduce sensitivity. The aims of this study using a placebo control were to assess the therapeutic value of amorphous calcium phosphate in dentine hypersensitivity and provide further information on the apparently natural improvement in the condition frequently observed in clinical trials. 38 subjects with dentine hypersensitivity affecting 1 tooth in each left and right sides of the jaws were recruited into this split mouth, randomised, double-blind study. At baseline, sensitivity was scored by the subjects on a 0-10 visual apologue scale after tactile, cool and cold water and evaporative stimulation of the test teeth. Active and control, water, solutions were then applied by a 2nd clinician. After 24 h, subjects returned for rescoring. On days 7 and 14, subjects were again rescored and the treatments reapplied. Further follow-up appointments for rescoring were on days 21, 28, 56 and 84. Plaque scores also were recorded from test teeth at each visit. Overall sensitivity decreased considerably and to a similar degree in test and control teeth with no consistent significant treatment difference. Plaque scores also decreased through the study period. It is concluded that either the amorphous calcium phosphate was without therapeutic effect or the activity was masked by the placebo response in the control teeth.
Yates
R
R
Division of Restorative Dentistry, Dental School, Bristol, UK.
Owens
J
J
Jackson
R
R
Newcombe
R G
RG
Addy
M
M
D000287:Administration, Topical; D000328:Adult; D000388:Air; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D003080:Cold Temperature; D003774:Dental Plaque Index; D003804:Dentin / Q000187:drug effects; D003807:Dentin Sensitivity / Q000188:drug therapy*; D003890:Desiccation; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D015990:Placebo Effect; D010919:Placebos; D014110:Touch
D002130:Calcium Phosphates; D010919:Placebos; C485828:alpha-tricalcium phosphate; C519480:amorphous calcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous